MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Screening risk of falls in Parkinson’s disease population living in underserved areas

    T. Capato, J. Miranda, F. Santos, R. Cury, E. Barbosa (São Paulo, Brazil)

    Objective: To verify the feasibility of the Balance-App to assess the risk of falls in the PD population living in underserved areas. Background: The screening…
  • 2023 International Congress

    The prevalence and clinical features of GBA-related Parkinson’s disease in a Slovak patient cohort

    A. Lackova, J. Necpal, V. Han, P. Pavelekova, K. Kulcsarova, T. Svorenova, L. Baranova, E. Tusay, B. Kovacova, E. Petro, B. Stasko, K. Burasova, M. Ostrozovicova, S. Bohacova, Z. Gdovinova, M. Skorvanek (Kosice, Slovakia)

    Objective: The aim of our study was to determine the prevalence and clinical characteristics of Slovak GBA-related patients with Parkinson's disease (PwP). Background: GBA variants…
  • 2023 International Congress

    A comparison of national data on Parkinson’s disease mortality between the USA and UK

    N. Smati, W. Lintiso, E. Shamim (Gaithersburg, USA)

    Objective: To evaluate recent mortality trends in Parkinson’s Disease (PD) between the United States of America (USA) and the United Kingdom (UK) per national healthcare…
  • 2023 International Congress

    Detection of freezing of gait in people with Parkinson’s disease using novel deep learning approaches.

    EC. Klaver, IB. Heijink, G. Silvestri, JPP. van Vugt, J. Nonnekes, RJA. van Wezel, MC. Tjepkema-Cloostermans (Nijmegen, Netherlands)

    Objective: To detect freezing of gait (FOG) in people with Parksinson’s disease using three novel deep learning approaches. Background: FOG is one of the most…
  • 2023 International Congress

    Improvements in Parkinson’s disease motor complications after treatment with opicapone: results from the OPTI-ON study

    C. Kilbane, R. Drake, O. Klepitskaya, M. Serbin, E. Jen, S. Rattana, J. Trotter, G. Liang (Cleveland, USA)

    Objective: To describe motor complications as measured by the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part IV in participants from the Opicapone Treatment…
  • 2023 International Congress

    Recommendations to tackle under-recognition and under-treatment of sialorrhea in Parkinson’s Disease: Is it time for a paradigm shift?

    B. Bergmans, V. Clark, S. Isaacson, T. Bäumer (Bruges, Belgium)

    Objective: To leverage patient survey data and expert opinion to develop recommendations for managing sialorrhea in patients with Parkinson’s disease (PD). Background: Sialorrhea, or drooling,…
  • 2023 International Congress

    Long-term evolution of advanced Parkinson’s disease burden: second interim results from the international PROSPECT observational study

    P. Sanchez Alonso, O. de Fabregues, A. Lehn, T. Oeda, F. Ory-Magne, D. Safarpour, L. Bergmann, P. Kukreja, K. Onuk, V. Fung (Majadahonda, Spain)

    Objective: To evaluate the long-term evolution of clinical and economic outcomes and treatment patterns of patients with advanced Parkinson’s disease (PD) who have symptoms that…
  • 2023 International Congress

    Association Between Anticholinergic Burden, MCI, and Cholinergic Denervation

    R. Paalanen, S. Roytman, P. Kanel, N. Bohnen (Ann Arbor, USA)

    Objective: To characterize the relationship between anticholinergic burden (ACB), mild cognitive impairment (MCI), and its underlying cholinergic pathology. Background: MCI is a common phenomenon in…
  • 2023 International Congress

    Foslevodopa/foscarbidopa in patients with advanced Parkinson’s disease: subgroup analyses from a phase 3, randomized study

    M. Soileau, N. Fisseha, A. Jeong, T. Kimber, K. Klos, W. Robieson, S. Talapala, E. Vaou, H. Zheng, M. Facheris, R. Hauser (Georgetown, USA)

    Objective: Present the efficacy and safety of 24-hour/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (LDP/CDP) across pre-specified subgroups (age, sex, body mass index [BMI], race,…
  • 2023 International Congress

    Developement and acceptability testing of a patient decision aid on levodopa/carbidopa intestinal gel.

    C-C. Cayer, IBB. Beaulieu-Boire, A-T. Tanguay (Sherbrooke, Canada)

    Objective: To develop a patient decision aid on levodopa/carbidopa intestinal gel (LCIG) and to test its acceptability. Background: : Advanced Parkinson’s disease (PD) is characterized…
  • « Previous Page
  • 1
  • …
  • 104
  • 105
  • 106
  • 107
  • 108
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley